RxDoctor Payments Data

Arnold Paul Cua, MD

Infectious Disease · Auburn, WANPI 1649243304

Payments from drug & device makers

$407in general payments, 2019–2025

Across 14 payments — averaging $29.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$100
  • GSK$91
  • Insmed, Inc.$70
  • AbbVie$46
  • Gilead$33
  • Johnson & Johnson$33
  • plus $33 from 2 others

What the payments were for

  • Food & beverage$39597%
  • Education$123%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$407 in reported general payments places this provider in the 60th percentile of 186 infectious disease providers in Washington.

See all infectious disease providers in Washington

Medicare billing

Part B allowed, 2024
$56,691
Medicare patients
105
Services billed
525

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala31$119,838
TivicayDolutegravir Sodium47$109,950
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf12$65,713
OdefseyEmtricitab/Rilpiviri/Tenof Ala13$47,347
TriumeqAbacavir/Dolutegravir/Lamivudi12$42,091
DescovyEmtricitabine/Tenofov Alafenam20$41,920
IsentressRaltegravir Potassium22$41,769
GenvoyaElviteg/Cob/Emtri/Tenof Alafen11$41,253
PrezcobixDarunavir/Cobicistat13$32,021
EdurantRilpivirine Hcl12$17,572
Etravirine12$12,554
ErtapenemErtapenem Sodium54$10,823
CefuroximeCefuroxime Axetil26$2,169
Doxycycline Hyclate36$1,962
Cephalexin28$1,796

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy, Genvoya$33$203,01162 claims
Viiv Healthcare CompanyTivicay, Triumeq$15$152,04159 claims
Johnson & JohnsonPrezcobix$33$32,02113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 186 infectious disease providers in Washington.

Other infectious disease in Auburn

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →